nach oben

Erschienen in:

01.05.2023 | Review

B lymphocytes in COVID-19: a tale of harmony and discordance

verfasst von: Amir Hossein Mansourabadi, Azin Aghamajidi, Maryam Dorfaki, Fatemeh Keshavarz, Zahra Shafeghat, Ali Moazzeni, Fahimeh Lavi Arab, Arezoo Rajabian, Mona Roozbehani, Reza Falak, Dr. Fatemeh Faraji, Dr. Reza Jafari

Erschienen in: Archives of Virology | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

B lymphocytes play a vital role in the human defense against viral infections by producing specific antibodies. They are also critical for the prevention of infectious diseases by vaccination, and their activation influences the efficacy of the vaccination. Since the beginning of coronavirus disease 2019 (COVID-19), which became the main concern of the world health system, many efforts have been made to treat and prevent the disease. However, for the development of successful therapeutics and vaccines, it is necessary to understand the interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, and the immune system. The innate immune system provides primary and nonspecific defense against the virus, but within several days after infection, a virus-specific immune response is provided first by antibody-producing B cells, which are converted after the resolution of disease to memory B cells, which provide long-term immunity. Although a failure in B cell activation or B cell dysfunction can cause a severe form of the disease and also lead to vaccination inefficiency, some individuals with B cell immunodeficiency have shown less production of the cytokine IL-6, resulting in a better disease outcome. In this review, we present the latest findings on the interaction between SARS-CoV-2 and B lymphocytes during COVID-19 infection.

Liu Y-C, Kuo R-L (2020) J.B.j. Shih, COVID-19: The first documented coronavirus pandemic in history. 43(4):328–333

Worldometer (2022) https:https://www.worldometers.info/coronavirus/

Ni W et al (2020) Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. 24(1):1–10

Zhou X, Ye QJFiI (2021) Cellular immune response to COVID-19 and potential immune modulators. 12:1566

Tang Y et al (2020) Cytokine storm in COVID-19: the current evidence and treatment strategies : p. 1708

Upasani V, Rodenhuis-Zybert I, Cantaert TJPp (2021) Antibody-independent Funct B cells Dur viral infections 17(7):e1009708

Agostinis C et al (2021) COVID-19, Pre-eclampsia and Complement System : p. 4744

Yu Y et al (2021) Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. 6(1):1–10

Shuwa HA et al (2021) Alterations in T and B cell function persist in convalescent COVID-19 patients. 2(6):720–735e4

10.

Quinti I et al (2020) A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. 146(1):211–213e4

11.

Baumgarth N et al (1999) Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. 96(5):2250–2255

12.

Baumgarth N et al (2000) B-1 and B-2 cell–derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. 192(2):271–280

13.

Moon H et al (2012) LPS-induced migration of peritoneal B-1 cells is associated with upregulation of CXCR4 and increased migratory sensitivity to CXCL12. 27(1):27–35

14.

Waffarn EE et al (2015) Infection-induced type I interferons activate CD11b on B-1 cells for subsequent lymph node accumulation. 6(1):1–11

15.

Aziz M et al (2015) The role of B-1 cells in inflammation. 63(1):153–166

16.

Peñaloza HF et al (2018) Interleukin 10 modulation of neutrophil subsets infiltrating lungs during Streptococcus pneumoniae infection. 13:12–16

17.

Popi AF, Lopes JD, Mariano MJI (2004) Interleukin-10 secreted by B‐1 cells modulates the phagocytic activity of murine macrophages in vitro. 113(3):348–354

18.

Wen W et al (2020) Author Correction: Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. 6(1):1–1

19.

Cao Y et al (2020) Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. 182(1):73–84e16

20.

Yemil Atisha Y, Diamond ZY (2019) B, B Cells and Generation of Antibodies

21.

Nutt SL et al (2015) The generation of antibody-secreting plasma cells. 15(3):160–171

22.

Cañete PF, Vinuesa CGJC (2020) COVID-19 makes B cells forget, but T cells remember. 183(1):13–15

23.

Paiano J et al (2019) Follicular B2 cell activation and class switch recombination depend on autocrine C3ar1/C5ar1 signaling in B2 cells. 203(2):379–388

24.

Jin X et al (2021) Global characterization of B cell receptor repertoire in COVID-19 patients by single-cell V (D) J sequencing. 22(6):bbab192

25.

Winklmeier S et al (2022) Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. 25(1):103659

26.

Grammatikos A et al (2021) Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies. Frontiers in Immunology, p 3454

27.

Zouali M (2011) Y.J.F.i.i. Richard, Marginal zone B-cells, a gatekeeper of innate immunity. 2:63

28.

Rubtsov AV et al (2008) TLR agonists promote marginal zone B cell activation and facilitate T-dependent IgM responses. 180(6):3882–3888

29.

Kotagiri P et al (2022) The impact of hypoxia on B cells in COVID-19 77: p. 103878

30.

Chen S et al (2022) The role of B cells in COVID-19 infection and vaccination 13

31.

Çölkesen F et al (2022) Memory B cells and serum immunoglobulins are associated with disease severity and mortality in patients with COVID-19.

32.

Reyes RA et al (2021) SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease. 16(12):e0261656

33.

Ciabattini A et al (2021) Evidence of SARS-CoV-2-specific memory B cells six months after vaccination with the BNT162b2 mRNA vaccine.12

34.

Gudbjartsson DF et al (2020) Humoral immune response to SARS-CoV-2 in Iceland. 383(18):1724–1734

35.

Iyer AS et al (2020) Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. 5(52):eabe0367

36.

Hartley GE et al (2020) Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. 5(54):eabf8891

37.

Dan J et al (2021) Memoria inmunológica al SARS-CoV-2 evaluada hasta 8 meses después de la infección. Ciencia

38.

Rodda LB et al (2021) Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. 184(1):169–183e17

39.

Boulanger M et al (2021) Peripheral plasma cells associated with mortality benefit in severe COVID-19: A marker of disease resolution. 134(8):1029–1033

40.

Turner JS et al (2021) SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans 595(7867): p. 421–425

41.

Sokal A et al (2021) Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. 184(5):1201–1213e14

42.

Kubánková M et al (2021) Physical phenotype of blood cells is altered in COVID-19. 120(14):2838–2847

43.

Ashrafi F et al (2021) Association of lymphocyte subsets with mortality in severe COVID-19 pneumonia patients. 35(11):e24046

44.

Palladino MJBm (2021) Complete blood count alterations in COVID-19 patients: A narrative review 31(3): p. 0–0

45.

Lagadinou M et al (2021) Alterations in lymphocyte subsets and monocytes in patients diagnosed with SARS-CoV-2 pneumonia: a mini review of the literature. 25(15):5057–5062

46.

Zhao Q et al (2020) Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. 96:131–135

47.

Zheng Y et al (2020) Comparative study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting uncontrolled inflammation might not be the main reason of tissue injury. : p. 2020.02. 19.20024885.

48.

Zhang Y et al (2021) Analysis of B cell receptor repertoires reveals key signatures of systemic B cell response after SARS-CoV-2 infection : p. JVI. 01600-21

49.

Laidlaw BJ, A.H.J.N.R.I., Ellebedy (2022) The germinal centre B cell response to SARS-CoV-2. 22(1):7–18

50.

Liu B et al (2020) Reduced numbers of T cells and B cells correlates with persistent SARS-CoV-2 presence in non-severe COVID-19 patients. 10(1):1–9

51.

Fang B, Q.H.J.C.R.i.C LS, Meng (2020) The laboratory’s role in combating COVID-19. 57(6):400–414

52.

Chan SS et al (2020) Peripheral lymphocyte substerations in COVID-19 patients

53.

Yang J et al (2021) Broad phenotypic alterations and potential dysfunction of lymphocytes in individuals clinically recovered from COVID-19. 13(3):197–209

54.

Abd Elhady MM et al (2022) Evaluation of peripheral lymphocyte subsets’ alteration and IL6 serum level correlated with Severity and outcome in Corona virus disease 2019 (COVID-19). 3(1):24–35

55.

Wu D et al (2021) Lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients. 21(1):1–12

56.

Murphy K, Weaver C (2016) Janeway’s immunobiology. Garland science

57.

Huang C et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China 395(10223):497–506

58.

Zhang B et al (2020) Clinical characteristics of 82 cases of death from COVID-19. 15(7):e0235458

59.

Jiang S, He Y (2005) J.E.i.d. Liu. SARS vaccine development 11(7):1016

60.

Chen I-Y et al (2019) Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome 10: p. 50

61.

Tay MZ et al (2020) The trinity of COVID-19: immunity, inflammation and intervention 20(6): p. 363–374

62.

Melenotte C et al (2020) Immune responses during COVID-19 infection 9(1): p. 1807836

63.

Huang Q et al (2019) Molecular basis of the differentiation and function of virus specific follicular helper CD4 + T cells. 10:249

64.

Röltgen K, Boyd SDJCH, Microbe (2021) Antibody and B cell responses to SARS-CoV-2 infection and vaccination. 29(7):1063–1075

65.

Mortaz E et al (2020) The immune response and immunopathology of COVID-19 : p. 2037

66.

Gaebler C et al (2021) Evolution of antibody immunity to SARS-CoV-2. 591(7851):639–644

67.

Sakharkar M et al (2021) Prolonged evolution of the human B cell response to SARS-CoV-2 infection. 6(56):eabg6916

68.

Wen W et al (2020) Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. 6(1):1–18

69.

Mansourabadi AH et al (2021) Serological and Molecular Tests for COVID-19: a recent update 18(1): p. 13

70.

Chen Y et al (2020) Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. 183(6):1496–1507e16

71.

Fenoglio D et al (2021) Characterization of T lymphocytes in severe COVID-19 patients. 93(9):5608–5613

72.

Mansourabadi AH et al (2020) The immune system as a target for therapy of SARS-CoV-2: a systematic review of the current immunotherapies for COVID-19. 258:118185

73.

Adamo S et al (2021) Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. 76(9):2866–2881

74.

Zhang J et al (2021) Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. 6(1):51–58

75.

Ellebedy AH et al (2016) Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. 17(10):1226–1234

76.

Krishnamurty AT et al (2016) Somatically hypermutated Plasmodium-specific IgM + memory B cells are rapid, plastic, early responders upon malaria rechallenge. 45(2):402–414

77.

Long Q-X et al (2020) Antibody responses to SARS-CoV-2 in patients with COVID-19. 26(6):845–848

78.

Lu LL et al (2018) Beyond binding: antibody effector functions in infectious diseases. 18(1):46–61

79.

Schäfer A et al (2021) Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. 218(3)

80.

Zohar T et al (2020) Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. 183(6):1508–1519e12

81.

Piccoli L et al (2020) Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. 183(4):1024–1042e21

82.

Anderson EM et al (2021) Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. 184(7):1858–1864e10

83.

Klein SL et al (2020) Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. 130(11):6141–6150

84.

Wu F et al (2020) Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

85.

Wang X et al (2020) Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. 71(10):2688–2694

86.

Jin J-M et al (2020) Gender differences in patients with COVID-19: focus on severity and mortality : p. 152

87.

Yehia BR et al (2020) Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals. 3(8):e2018039–e2018039

88.

Vanshylla K et al (2021) Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. 29(6):917–929e4

89.

Suthar MS et al (2020) Rapid generation of neutralizing antibody responses in COVID-19 patients 1(3): p. 100040

90.

Lee WT et al (2021) Neutralizing antibody responses in COVID-19 convalescent sera 223(1): p. 47–55

91.

Sanaei M-J et al (2021) New insights into regulatory B cells biology in viral, bacterial, and parasitic infections 89: p. 104753

92.

Das A et al (2012) IL-10–producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. 189(8):3925–3935

93.

Horikawa M et al (2013) Regulatory B cell (B10 Cell) expansion during Listeria infection governs innate and cellular immune responses in mice. 190(3):1158–1168

94.

Maroof A et al (2008) Posttranscriptional regulation of il10 gene expression allows natural killer cells to express immunoregulatory function. 29(2):295–305

95.

Belkaid Y et al (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti–IL-10 receptor antibody for sterile cure. 194(10):1497–1506

96.

Zhang M et al (2014) Anti-tuberculosis treatment enhances the production of IL-22 through reducing the frequencies of regulatory B cell. 94(3):238–244

97.

Gong Y et al (2015) Role of IL-10-producing regulatory B cells in chronic hepatitis B virus infection. 60(5):1308–1314

98.

Liu Y et al (2016) IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection. 130(11):907–919

99.

Rodríguez Y et al (2020) Autoinflammatory and autoimmune conditions at the crossroad of COVID-19 114: p. 102506

100.

Moody R et al (2021) Adaptive Immunity and the Risk of Autoreactivity in COVID-19 22(16): p. 8965

101.

Ramaswamy A et al (2021) Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. 54(5):1083–1095e7

102.

Knight JS et al (2021) The intersection of COVID-19 and autoimmunity 131(24)

103.

Salle VJCI (2021) Coronavirus-induced Autoimmun 226:108694

104.

Opdenakker G, Van Damme JJC (2021) and g.f. reviews, Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity 58: p. 134–140

105.

Dotan A et al (2021) The SARS-CoV-2 as an instrumental trigger of autoimmunity. 20(4):102792

106.

Taeschler P et al (2022) Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures

107.

Lleixà C et al (2021) Autoantibody Screen Guillain–Barré syndrome 18(1):1–13

108.

Babaei M et al (2022) The Effect of COVID-19 Pandemic on Patients with Primary Immunodeficiency: A Cohort Study. Iran J Med Sci 47(2):162PubMedPubMedCentral

109.

Mira E et al (2020) Rapid recovery of a SARS-CoV-2–infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunology: Pract 8(8):2793–2795

110.

Jin H et al (2020) Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunology: Pract 8(10):3594–3596e3

111.

Pulvirenti F et al (2020) Health-related quality of life in common variable immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic. J Allergy Clin Immunology: Pract 8(6):1894–1899e2

112.

Ferrari S et al (2021) Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma 62(6):1490–1496CrossRefPubMed

113.

Soresina A et al (2020) Two X-linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover. Pediatr Allergy Immunol 31(5):565–569CrossRefPubMedPubMedCentral

114.

Quinti I et al (2020) A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol 146(1):211–213e4CrossRefPubMedPubMedCentral

115.

Arkatkar T et al (2017) B cell–derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity. J Exp Med 214(11):3207–3217CrossRefPubMedPubMedCentral

116.

Tuano KS et al (2021) Secondary immunodeficiencies: An overview 127(6): p. 617–626

117.

Castelo-Branco C, Soveral I (2014) The immune system and aging: a review. Gynecol Endocrinol 30(1):16–22CrossRefPubMed

118.

Ueda M et al (2018) Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Rev 32(2):106–115CrossRefPubMed

119.

Oppong E, Cato AC (2015) Effects of glucocorticoids in the immune system Glucocorticoid signaling, : p. 217–233

120.

Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17(4):233–247CrossRefPubMedPubMedCentral

121.

Davids MS, Brown JR (2014) Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol 10(6):957–967CrossRefPubMed

122.

Duléry R et al (2021) Prolonged in-hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy. Am J Hematol 96(8):934–944CrossRefPubMedPubMedCentral

123.

Suárez-Díaz S et al (2021) Mild COVID-19 in ANCA-associated vasculitis treated with rituximab. Ann Rheum Dis 80(6):e99–e99CrossRefPubMed

124.

Ma SQ et al (2020) Glucocorticoid therapy delays the clearance of SARS-CoV‐2 RNA in an asymptomatic COVID‐19 patient. Journal of medical virology

125.

Balashov D et al (2021) SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation. Transfus Apheres Sci 60(1):102983CrossRef

126.

Çınar OE et al (2020) Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. Transfus Apheres Sci 59(5):102821CrossRef

Titel: B lymphocytes in COVID-19: a tale of harmony and discordance
verfasst von: Amir Hossein Mansourabadi
Azin Aghamajidi
Maryam Dorfaki
Fatemeh Keshavarz
Zahra Shafeghat
Ali Moazzeni
Fahimeh Lavi Arab
Arezoo Rajabian
Mona Roozbehani
Reza Falak
Dr. Fatemeh Faraji
Dr. Reza Jafari
Publikationsdatum: 01.05.2023
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 5/2023
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-023-05773-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Identification of functional pathways and potential genes associated with interferon signaling during human adenovirus type 7 infection by weighted gene coexpression network analysis

Identification and management of tomato brown rugose fruit virus in greenhouses in Mexico

Correction to: Whole‑genome sequence analysis of a novel orthobunyavirus isolated in Japan in the 1980s

Complete genome sequence analysis of a novel citlodavirus isolated from the leaves of Myrica rubra in Yunnan

Epidemiological study of unusual rotavirus strains and molecular characterization of emerging P[14] strains isolated from children with acute gastroenteritis during a 15-year period